multiple selective kinase inhibitors (Maxocore)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namemultiple selective kinase inhibitors (Maxocore)
Drug Alias NameMC-2002 (MaxoCore)dual Flt3/ABL inhibitors (MaxoCore)MC-2001MC-2006
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsBcr-Abl tyrosine kinase inhibitorsAnticancer protein kinase inhibitors
TargetsBcr-Abl tyrosine kinaseTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMaxoCore Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMaxoCore Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A